Revatio Pfizer Inc. - Treatment for Pulmonary Arterial Hypertension
Revatio contains sildenafil citrate, the active ingredient in the erectile dysfunction medication Viagra. Revatio is indicated for the treatment of pulmonary arterial hypertension (PAH), a rare, aggressive and life-shortening vascular disease.Posted: June 2005
Related articles
- FDA Approves Intravenous Formulation Of Pfizer's Revatio (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension - November 20, 2009
- Pfizer Submits Regulatory Filings for Revatio as a Treatment for Pulmonary Arterial Hypertension - December 3, 2004
Revatio (sildenafil citrate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
